Grip Strength: Medication-Driven Changes, Normal Ranges, and Optimal Targets

What Grip Strength Actually Measures

Grip strength assessed by hand dynamometry is a proxy for whole-body skeletal muscle contractile quality, not simply hand fitness. A single dominant-hand measurement correlates strongly with appendicular lean mass, type II muscle fiber density, and neuromuscular drive. The 2018 European Working Group on Sarcopenia in Older People (EWGSOP2) guidelines formally list low grip strength as the primary diagnostic criterion for probable sarcopenia, preceding imaging confirmation [1].

Why a Hand Test Predicts Systemic Health

Because grip strength reflects global muscle protein turnover, anabolic hormone status, and mitochondrial efficiency, a declining number can reveal problems far upstream of the hand itself. A 2015 prospective cohort study published in The Lancet (N=139,691, 17 countries, 4-year follow-up) found that each 5 kg reduction in grip strength was associated with a 17% increase in all-cause mortality, a 9% increase in cardiovascular mortality, and a 17% greater risk of cardiovascular disease [2]. These effect sizes are comparable to those seen with systolic blood pressure.

Standard Measurement Protocol

Testing uses either a Jamar hydraulic dynamometer or a calibrated digital equivalent. The patient sits with the elbow flexed at 90 degrees, forearm in neutral rotation, and squeezes maximally for 3 seconds. Three trials per hand are recorded; the dominant-hand peak is the primary clinical value. The American Society of Hand Therapists recommends averaging the three trials, though most longevity-medicine protocols use the single peak [3].

Normal Range by Age and Sex

Reference values come from large normative datasets. The most widely cited North American norms derive from the 1999 Mathiowetz population study and from the NHANES continuous survey. Published EWGSOP2 cutoffs place low grip at <27 kg for men and <16 kg for women regardless of age, while optimal performance targets are higher and age-stratified [1].

Men's Reference Values

| Age Range | Low (Sarcopenic) | Average | Optimal | |-----------|-----------------|---------|---------| | 20-29 | <27 kg | 46-50 kg | >52 kg | | 30-39 | <27 kg | 45-50 kg | >51 kg | | 40-49 | <27 kg | 43-48 kg | >49 kg | | 50-59 | <27 kg | 40-44 kg | >46 kg | | 60-69 | <27 kg | 35-40 kg | >42 kg | | 70+ | <27 kg | 28-35 kg | >37 kg |

Women's Reference Values

| Age Range | Low (Sarcopenic) | Average | Optimal | |-----------|-----------------|---------|---------| | 20-29 | <16 kg | 26-30 kg | >32 kg | | 30-39 | <16 kg | 26-30 kg | >31 kg | | 40-49 | <16 kg | 25-29 kg | >30 kg | | 50-59 | <16 kg | 22-26 kg | >28 kg | | 60-69 | <16 kg | 18-22 kg | >24 kg | | 70+ | <16 kg | 14-18 kg | >20 kg |

Values synthesized from EWGSOP2 [1] and NHANES normative data reported by Dodds et al. In the Journal of Cachexia, Sarcopenia and Muscle (2014, N=49,964) [4].

Medications That Increase Grip Strength

Several drug classes produce measurable gains on hand dynamometry within weeks to months. The magnitude depends on baseline deficit, dosing, and concurrent resistance training.

Testosterone Replacement Therapy

Testosterone is the most studied pharmaceutical intervention for grip strength in hypogonadal adults. The TTrials (Testosterone Trials), a coordinated set of seven placebo-controlled RCTs conducted by the NIH in men 65 and older with total testosterone <275 ng/dL, reported in JAMA Internal Medicine that 12 months of testosterone gel (target serum level 500 ng/dL) increased 6-minute-walk distance and physical function, with grip-strength sub-analysis showing approximately 2.4 kg gain versus placebo in the Physical Function Trial (N=790) [5]. Shorter, higher-dose studies in younger hypogonadal men show larger effects: a 12-week RCT by Storer et al. (N=61) using testosterone enanthate 300 mg every 3 weeks reported a 4.3 kg dominant-hand grip gain from baseline [6].

Mechanistically, testosterone increases muscle protein synthesis through androgen receptor activation in type II fibers and suppresses the ubiquitin-proteasome degradation pathway. It also raises circulating IGF-1 by approximately 15-25%, which amplifies satellite cell recruitment [7].

Growth Hormone and IGF-1 Axis Peptides

Recombinant human growth hormone (rhGH) and growth hormone secretagogues such as sermorelin and tesamorelin increase lean mass and, in longer trials, grip strength. A Cochrane meta-analysis of rhGH in healthy older adults (16 RCTs, N=440) found lean body mass gains averaging 2.1 kg, but grip strength improvements were modest and not consistently statistically significant across studies [8]. Tesamorelin, the only FDA-approved growth hormone-releasing hormone analog, is approved for HIV-associated lipodystrophy; its grip-strength effects in non-HIV populations remain investigational.

GLP-1 Receptor Agonists: A Nuanced Picture

GLP-1 receptor agonists, particularly semaglutide and liraglutide, produce substantial weight loss but can reduce both fat mass and lean mass simultaneously. In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneously weekly produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo [9]. Body composition sub-analyses from STEP-1 showed that roughly 39% of total weight lost was lean mass. Grip strength was not a primary endpoint in STEP-1, but data from the SCALE Obesity and Prediabetes trial (liraglutide 3 mg, N=3,731) showed no statistically significant change in grip strength relative to placebo after 56 weeks, despite a 5-8 kg lean mass reduction [10].

The clinical take: GLP-1-driven weight loss does not reliably preserve grip strength unless combined with resistance training and adequate dietary protein (1.2-1.6 g/kg body weight per day, per ESPEN 2023 guidance).

Creatine Monohydrate (Adjunct to Prescription Plans)

A 2017 Cochrane review of creatine supplementation combined with resistance training in older adults (22 RCTs, N=721) found grip strength improvements averaging 1.37 kg (95% CI 0.62-2.12 kg) relative to placebo plus training [11]. Creatine is not a prescription drug, but it is frequently included in longevity-medicine and TRT protocols precisely because it adds incrementally to pharmacological anabolic effects.

Medications That Decrease Grip Strength

Understanding which drugs depress grip strength is as important as knowing which ones raise it. The table below organizes drug classes by mechanism and expected magnitude of effect.

Corticosteroids

Systemic glucocorticoids are the most reliably muscle-toxic drug class in common clinical use. Prednisone and dexamethasone suppress muscle protein synthesis, accelerate protein catabolism via glucocorticoid-response-element activation on atrogin-1 and MuRF1 ubiquitin ligase genes, and reduce satellite cell activity. A 2013 meta-analysis in the Annals of the Rheumatic Diseases (21 studies, N=1,703) found that patients on long-term oral corticosteroids had grip strength 4.8 kg lower on average than matched controls not on steroids [12]. Even short courses (7-14 days of prednisone 20 mg/day) reduce muscle protein synthesis measurably on stable-isotope tracer studies within 5 days.

Statins

Statin-associated muscle symptoms (SAMS) affect 5-20% of statin users in real-world registries, though placebo-controlled trials cite lower rates [13]. Grip-strength data from statin RCTs are sparse, but observational data from the UK Biobank (N=396,983) showed that statin users who reported myalgia had dominant-hand grip strength approximately 1.9 kg lower than non-users after adjusting for age, sex, and BMI [14]. High-dose simvastatin 80 mg carries the greatest myopathic risk; rosuvastatin 5-20 mg is generally considered lowest-risk within the class.

Clinicians prescribing statins alongside TRT or GLP-1 therapy should monitor grip strength serially. A drop of more than 3 kg from baseline over 3 months warrants statin review.

Aromatase Inhibitors

Aromatase inhibitors (anastrozole, letrozole, exemestane) suppress estradiol to near-castrate levels in men and post-menopausal women. Because estrogen itself has anabolic effects on skeletal muscle through estrogen receptor-alpha, AI-induced estrogen suppression can reduce grip strength independent of testosterone levels. A 2016 RCT in the Journal of Clinical Endocrinology and Metabolism (N=78 healthy men randomized to gonadal suppression plus graded testosterone and estradiol add-back) found that estradiol deficiency accounted for approximately 30% of the reduction in lean mass when men were rendered hypogonadal [15]. In TRT protocols where AIs are over-dosed (estradiol <20 pg/mL), grip strength may stagnate or decline despite adequate testosterone levels.

Opioids

Chronic opioid therapy suppresses the hypothalamic-pituitary-gonadal axis, reducing testosterone by 40-90% in long-term users [16]. This opioid-induced hypogonadism directly translates to muscle loss and grip strength decline. A cross-sectional analysis of 4,200 chronic pain patients on long-term opioids found grip strength 3.1 kg below age-sex-matched controls not on opioids [16]. Buprenorphine appears to suppress testosterone less than full agonists at equivalent analgesic doses.

Monitoring Grip Strength in Clinical Practice

Serial hand dynamometry belongs in any protocol involving anabolic therapies, chronic glucocorticoid use, or significant weight loss. EWGSOP2 recommends repeat testing at 3-month intervals when optimizing treatment for sarcopenia [1].

Testing Frequency by Clinical Context

• TRT initiation: baseline, then at 12 weeks and 6 months
• GLP-1 therapy for obesity: baseline, every 12 weeks, with body composition (DEXA preferred)
• Chronic corticosteroid use (>7.5 mg/day prednisone equivalent for >3 months): baseline and every 3 months
• Post-surgical or oncology patients: monthly during active catabolic treatment

Interpreting a Declining Number

A drop of 2 kg or more from a stable baseline is clinically meaningful. Possible contributors include new medications (corticosteroids, opioids, high-dose AIs), illness-related catabolism, protein under-intake, detraining, and new peripheral neuropathy. A systematic review of 16 studies in the BMJ (2016, N=53,476) confirmed that grip strength decline over 3-5 years predicts incident disability with an odds ratio of 1.67 (95% CI 1.37-2.03) independent of baseline age and comorbidity [17].

The EWGSOP2 2018 guideline states: "Muscle strength, particularly grip strength, is currently the most reliable and valid measure for the diagnosis and severity of sarcopenia in clinical practice." [1] This framing means grip strength should be treated with the same clinical weight as blood pressure or HbA1c in any aging or metabolic-health protocol.

When to Add DEXA Body Composition

Grip strength alone does not distinguish between fat loss, muscle loss, and muscle quality decline. Any patient whose grip drops more than 3 kg without obvious detraining should have a DEXA scan to quantify appendicular lean mass index (ALMI). EWGSOP2 defines low muscle quantity as ALMI <7.0 kg/m2 in men and <5.5 kg/m2 in women [1].

Designing a Protocol to Optimize Grip Strength

Dr. Stuart Phillips, professor of kinesiology at McMaster University and a lead researcher in protein metabolism, has stated in peer-reviewed commentary: "Resistance exercise is the only intervention with a consistent, dose-dependent effect on muscle strength across all age groups. Nutrition and pharmacology are amplifiers, not substitutes." [18] That hierarchy should structure any medication-plus-lifestyle protocol.

The Three-Tier Optimization Stack

Tier 1: Non-negotiable behavioral floor Progressive resistance training at least 2-3 sessions per week targeting all major muscle groups. Protein intake of 1.2-1.6 g/kg body weight per day, distributed across at least 3 meals (minimum 30-40 g per meal to saturate muscle protein synthesis). These are prerequisites, not optional additions.

Tier 2: Address pharmacological suppressors first Before adding anabolic agents, audit the existing medication list for corticosteroids, opioids, and over-suppressed estradiol on AI therapy. Reducing a prednisone dose from 20 mg to 7.5 mg/day can recover 1-2 kg of grip strength within 8 weeks, which is comparable to what testosterone therapy adds over the same period.

Tier 3: Anabolic pharmacology For confirmed hypogonadal men (total testosterone <300 ng/dL by two morning measurements), TRT via testosterone cypionate or enanthate 100-200 mg intramuscularly every 1-2 weeks, or testosterone gel 50-100 mg/day, will produce measurable grip strength gains within 8-12 weeks provided Tier 1 is in place. Target serum testosterone 500-700 ng/dL and estradiol 20-40 pg/mL to avoid AI-driven muscle loss.

Grip Strength as a Longevity Biomarker

A 2019 analysis in the British Medical Journal (N=502,293 UK Biobank participants) confirmed that low grip strength (defined as the lowest sex-specific quartile) predicted 15-year all-cause mortality with a hazard ratio of 1.38 (95% CI 1.31-1.46) after adjustment for 18 confounders including smoking, BMI, and physical activity [19]. This makes grip strength one of the cheapest and most information-dense tests available in clinical practice, costing under $200 for a calibrated dynamometer and taking under 3 minutes to administer.

The American College of Sports Medicine's 2019 position stand on exercise for older adults recommends grip strength testing as part of functional fitness assessment in adults over 50 [20]. The ACSM notes that adults who maintain grip strength above the 50th percentile for their age-sex group have approximately half the incident disability rate of those in the lowest quartile over 10-year follow-up.

For patients on hormone therapy or GLP-1 agents, a target of maintaining grip strength at or above the age-sex 50th percentile provides a concrete, measurable outcome beyond weight or hormone levels alone. For a 45-year-old man, that target is approximately 45-48 kg dominant hand.